美多巴联合盐酸司来吉兰治疗帕金森患者的临床效果及影响

doi:10.3969/j.issn.1000-8535.2022.05.020

摘要/Abstract

摘要： 目的探讨美多巴联合盐酸司来吉兰治疗帕金森患者的临床效果及对不良反应情况的影响。方法选取我院2018年1月—2020年12月收治的96例帕金森患者,通过单双号抽签法将96例患者分为2组,分别为对照组、观察组(每组48例)。对照组给予美多巴治疗,观察组在美多巴联合盐酸司来吉兰进行治疗。然后对比2组患者治疗前后的临床疗效,采用帕金森统一评分量表计算精神状态、运动功能和日常活动评分并记录不良反应的发生率。结果对比2组患者治疗前后临床疗效,观察组患者临床总有效率高于对照组(87.50% vs 66.66%),差异有统计学意义(χ²=5.897,P=0.015);治疗后2组患者精神状态、运动功能和日常活动评分低于治疗前(P<0.05),且观察组患者各项评分低于对照组,差异有统计学意义(t=8.250,P<0.001;t=4.388,P=<0.001;t=3.207,P=0.002);对比2组患者不良反应发生率,对照组与观察组不良反应发生率比较无差异(10.41% vs 12.50%,χ²=0.103,P=0.749),2组患者治疗后的不良反应均为一过性,停药或休息后可自行缓解。结论美多巴联合盐酸司来吉兰治疗帕金森患者的临床疗效良好,能让患者精神状态、运动功能和日常生活得到显著改善,且不良反应较少。

关键词: 美多巴, 盐酸司来吉兰, 帕金森病, 临床疗效, 不良反应

Abstract: Objective To explore the clinical effect of medopa combined with selegiline hydrochloride in the treatment of patients with Parkinson's disease and its impact on adverse reactions. Methods A total of 96 Parkinson's disease patients from January 2018 to December 2020 were selected and divided into two groups by the odd and even number drawing method, 48 cases each. The control group was treated with medopa, and the observation group was treated with selegiline hydrochloride on the basis of the control group. Then the clinical efficacy of the two groups were compared, and the Unified Parkinson's Disease Rating Scale was used to access the mental state, motor function and daily activity scores of the patients, and the incidence of adverse reactions was recorded. Results The total effective rate of the observation group was higher than that of the control group (87.50% vs 66.66%), with statistical significance(χ²=5.897,P=0.015). After treatment, the scores of mental state, motor function and daily activities were lower (P<0.05), and the scores of the observation group were significantly lower than those of the control group (t=8.250, P<0.001; t=4.388, P=<0.001; t=3.207, P=0.002);the incidence of adverse reactions had no differences (10.41% vs 12.50%, χ²=0.103, P=0.749). The adverse reactions were transient, which could be alleviated by drug withdrawal or rest. Conclusions Madopa combined with selegiline hydrochloride had a good clinical effect in the treatment of patients with Parkinson's disease. It could significantly improve the mental state, motor function and daily life of patients, with less adverse reaction, which is worthy of promotion.

Key words: medopa, selegiline hydrochloride, Parkinson's disease, clinical efficacy, adverse reaction

邱凌骐, 邱浩强, 陈松深. 美多巴联合盐酸司来吉兰治疗帕金森患者的临床效果及影响[J]. 广州医药, 2022, 53(5): 97-100.

QIU Lingqi, QIU Haoqiang, CHEN Songshen. Clinical effect and influence of medopa combined with selegilan hydrochloride in the treatment of patients with Parkinson's disease[J]. Guangzhou Medical Journal, 2022, 53(5): 97-100.

参考文献

[1] 杜广清,方伯言,刘爱贤,等. 帕金森病患者康复治疗药物利用研究[J]. 中国医药, 2020, 15(11):140-144.
[2] 赵琴琴, 张威, 王佩,等. 临床药师在晚期帕金森病伴复杂运动并发症中的药学服务[J]. 中国现代应用药学, 2020, 37(4):87-90.
[3] 彭蔚, 欧阳樱君, 余健敏,等. 济川煎加减结合贴穴治疗脾肾阳虚型帕金森病患者便秘[J]. 广州医药, 2020, 51(3):58-61.
[4] 农英瑭. 盐酸司来吉兰联合美多巴治疗帕金森病的疗效及安全性[J]. 当代医药论丛, 2020,18(17):167-168.
[5] 付经桥. 美多巴联合盐酸司来吉兰治疗帕金森病的疗效和安全性分析[J]. 当代医学, 2019, 25(36):85-87.
[6] 李陶乐, 唐北沙, 郭纪锋. 帕金森病再现性震颤的机制探讨[J]. 中华神经科杂志, 2020, 53(7):544-547.
[7] 宋晓萌, 孟茜, 历静,等. 帕金森病患者跌倒相关因素的研究进展[J]. 临床神经病学杂志, 2020, 33(1):74-77.
[8] 陈艳红, 杨凤翔, 张东云,等. 电针联合康复训练治疗帕金森病的临床研究[J]. 中国康复, 2012, 27(6):426-428.
[9] 许超峰. 美多巴联合盐酸司来吉兰治疗帕金森病的临床疗效分析[J]. 现代诊断与治疗, 2020, 32(20):57-58.
[10] 李陶乐, 唐北沙, 郭纪锋. 帕金森病再现性震颤的机制探讨[J]. 中华神经科杂志, 2020, 53(7):544-547.
[11] 池洁珊, 张玉虎. 进展期帕金森病的识别与治疗策略[J]. 中风与神经疾病杂志, 2019, 36(11):5-9.
[12] 马春潮, 朱晓冬. 帕金森病认知障碍[J]. 中国实用内科杂志, 2019, 39(9):769-774.
[13] 王阳, 徐冰, 周进,等. 司来吉兰联合普拉克索对帕金森病合并睡眠障碍患者精神行为症状认知障碍及日常生活能力的影响[J]. 河北医学, 2019, 25(7):1078-1081.
[14] 路书静. 美多巴联合盐酸司来吉兰治疗帕金森病的疗效评价[J]. 中国农村卫生, 2019, 11(18):23-24.
[15] 任可钰. 盐酸司来吉兰联合多巴丝肼片对帕金森病患者认知功能,不良反应及生命质量的影响[J]. 中国现代药物应用, 2020, 14(22):218-220.